Spontaneous Remission in a Patient with Chronic Myeloid Leukemia: A Case Report.

Awni Alshurafa, Yeslem Ekeibed, Susanna Akiki, Muna Alzeyara, Zafar Nawaz, Mohamed A Yassin

Open access · goldAbstract readCase Reports

In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.9field-weighted citation impact, top 22% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)-Case No. 2: Treatment-Free Remission After 9 Years of Imatinib Treatment Without Prior Achievement of Sustained Deep Molecular Response.Case reports in oncological medicine · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Awni AlshurafaDepartment of Hematology, Hamad Medical Corporation, Doha, Qatar.

Yeslem EkeibedDepartment of Hematology, Hamad Medical Corporation, Doha, Qatar.

Susanna AkikiDepartment of Diagnostic Laboratory, Hamad Medical Corporation, Doha, Qatar.

Muna AlzeyaraDepartment of Diagnostic Laboratory, Hamad Medical Corporation, Doha, Qatar.

Zafar NawazDepartment of Diagnostic Laboratory, Hamad Medical Corporation, Doha, Qatar.

Mohamed A YassinDepartment of Hematology, Hamad Medical Corporation, Doha, Qatar.

Hamad Medical Corporation · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm in which granulocytic cells are the main proliferative component. At diagnosis, more than 90% of CML cases have the characteristic Philadelphia chromosome, containing the

Indexed as

Chronic myeloid leukemiaPhiladelphia chromosomeSpontaneous remissionTyrosine kinase inhibitors

Identifiers

PMID37900818

DOI10.1159/000533660

PMCPMC10601788

OpenAlexW4387521750

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.